Meropenem and Empyema - a phase IV clinical study of FDA data

Summary:

Empyema is reported as a side effect among people who take Meropenem (meropenem), especially for people who are male, 60+ old, also take Vancomycin, and have Infection.

The phase IV clinical study analyzes which people have Empyema when taking Meropenem. It is created by eHealthMe based on reports of 33,250 people who have side effects when taking Meropenem from the FDA, and is updated regularly.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

What is Empyema?

Empyema (collection of pus in a cavity in the body) is found to be associated with 357 drugs and 514 conditions by eHealthMe. Check the latest studies of Empyema.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

33,250 people reported to have side effects when taking Meropenem.
Among them, 25 people (0.08%) have Empyema.

Among these 25 people:

What is the gender of people who have Empyema when taking Meropenem? *

female: 19.05 %
male: 80.95 %

What is the age of people who have Empyema when taking Meropenem? *

What are other drugs people take besides Meropenem? *

What are other side effects people have besides Empyema? *

Pneumonia: 9 people, 36.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 8 people, 32.00%
Drug Ineffective: 5 people, 20.00%
Pleural Effusion (water on the lungs): 4 people, 16.00%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 4 people, 16.00%
Escherichia Sepsis (bacterial infection by escherichia coli): 3 people, 12.00%
Mucormycosis (a rare infection caused by organisms that belong to a group of fungi called mucoromycotina): 3 people, 12.00%
Inflammatory Marker Increased: 3 people, 12.00%
Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung): 3 people, 12.00%
Septic Shock (shock due to blood infection): 3 people, 12.00%

What are the existing conditions these people have? *

Infection: 5 people, 20.00%
Pneumonia: 4 people, 16.00%
Escherichia Infection (bacterial infection by escherichia coli): 3 people, 12.00%
Mucormycosis (a rare infection caused by organisms that belong to a group of fungi called mucoromycotina): 3 people, 12.00%
Staphylococcal Infection (an infection with staphylococcus bacteria): 3 people, 12.00%
Pneumonia Bacterial (pneumonia associated with bacterial infection): 3 people, 12.00%
Inflammation: 2 people, 8.00%
Pleural Infection (infection of membrane of lungs): 2 people, 8.00%
Escherichia Sepsis (bacterial infection by escherichia coli): 2 people, 8.00%
Infectious Pleural Effusion (infectious fluid in the lung): 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Meropenem and have Empyema?

- Check whether Empyema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Meropenem:

Meropenem (33,295 reports)

Empyema treatments and more:

Empyema (2,709 reports)

Browse all side effects of Meropenem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Empyema:

Empyema (357 drugs)

Browse all the conditions that are associated with Empyema:

Empyema (514 conditions)

Related publications that referenced our studies

Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on meropenem (the active ingredients of Meropenem) and Meropenem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.